News
The Calypso trial (NCT05778071) of eneboparatide, an investigational parathyroid hormone (PTH) receptor 1 agonist, met its primary endpoint of a composite of normalisation of albumin-adjusted serum ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback